In these videos, Dr Ilan Melnick, Chief Medical Officer at Passageway Residences of Miami-Dade County, discusses his clinical experience with Abilify Asimtufii®, including how the safety compares with the results from the published pharmacokinetic study, and how to help make gluteal injections more acceptable to patients.
Abilify Asimtufii PBS Information: Authority required (STREAMLINED) Code: 16456 for Schizophrenia. This product is not listed on the PBS for the treatment of Bipolar I disorder
Please review Approved Product Information before prescribing. Product Information is available here or by calling Lundbeck on 1300 721 277
Abilify Asimtufii® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Level 2/9 Help St, Chatswood NSW 2067, Abilify Asimtufii® is co-commercialised by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Ltd.
.
